1 | Organs involved in MS | 78(86.7) | 85(100)§ | 23(92)§ | 186(93)§ |
2 | CNS composition | 51(56.7) | 54(63.5) | 16(64) | 121(60.5) |
4† | MS impact on life expectancy | 32(35.6) | 66(77.6) | 23(92)§ | 121(60.5) |
5 | MS as immune disease | 63(70) | 71(83.5) | 24(96)§ | 158(79) |
6 | MS as a contagious disease | 71(78.9) | 85(100)§ | 25(100)§ | 181(90.5)§ |
7 | MS etiology | 8(8.9)‡ | 7(8.2)‡ | 11(44) | 26(13)‡ |
8 | MS transmission to offspring | 43(47.8) | 65(76.5) | 21(84) | 129(64.5) |
9 | MS transmission to other family member | 9(10)‡ | 18(21.2)‡ | 15(60) | 42(21)‡ |
10 | Myelin/axon damage | 50(55.6) | 71(83.5) | 18(72) | 139(69.5) |
11 | Age of onset | 56(62.2) | 76(89.4) | 23(92)§ | 155(77.5) |
12 | Sex ratio in MS prevalence | 67(74.4) | 80(94.1)§ | 25(100)§ | 172(86) |
13 | Myelin function | 48(53.3) | 72(84.7) | 22(88) | 142(71) |
14 | Tests used to diagnose MS | 20(22.2)‡ | 24(28.2) | 13(52) | 57(28.5) |
15 | Role of MRI in MS diagnosis | 85(94.4)§ | 83(97.6)§ | 25(100)§ | 193(96.5)§ |
16 | Role of gadolinium injections during MRI | 7(7.8)‡ | 17(20)‡ | 13(52) | 37(18.5)‡ |
17 | Role of MRI in disease follow up | 62(68.9) | 78(91.8)§ | 25(100)§ | 165(82.5) |
18 | Role of lumbar puncture | 22(24.4)‡ | 45(52.9) | 22(88) | 89(44.5) |
19 | Frequency of lumbar puncture | 17(18.9)‡ | 46(54.1) | 21(84) | 84(42) |
21† | Definition of remittent MS | 13(14.4)‡ | 43(50.6) | 18(72) | 74(37) |
22 | Benign MS | 12(13.3)‡ | 34(40) | 19(76) | 65(32.5) |
23 | Impact of pregnancy on MS | 30(33.3) | 73(85.9) | 23(92)§ | 126(63) |
24 | Curative treatment | 74(82.2) | 84(98.8)§ | 24(96)§ | 182(91)§ |
25 | Types of MS disease targeted by current therapies | 25(27.8) | 31(36.5) | 13(52) | 69(34.5) |
*MSKQ multiple sclerosis Knowledge questionnaire (taken with permission from Giordano et al. 2010), † question number 3 and 20 are deleted from the MSKQ (refer to text for explanation), (‡ = <25%, § = >90%) |